Schering AG/Chiron Betaseron Label Expansion For Early MS Expected By Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental BLA filing could provide early-use labeling similar to that of Biogen Idec’s market leading Avonex by year-end.